Eversense 365-day System
Continuous Glucose Monitoring for Diabetes
CE Mark ApprovedCommercial (Europe); Pre-submission (U.S.)
Key Facts
Indication
Continuous Glucose Monitoring for Diabetes
Phase
CE Mark Approved
Status
Commercial (Europe); Pre-submission (U.S.)
Company
About Senseonics
Senseonics Holdings, Inc. is a commercial-stage medical device company with a mission to revolutionize diabetes care via its long-term, implantable CGM platform. Its flagship Eversense system, approved for 180-day wear in the US and 365-day wear in Europe, represents a significant technological differentiation in a market dominated by short-term, transcutaneous sensors. The company's strategy hinges on leveraging its proprietary fluorescent sensor technology and a global commercialization partnership with Ascensia Diabetes Care to capture market share in the multi-billion-dollar CGM landscape.
View full company profileTherapeutic Areas
Other Continuous Glucose Monitoring for Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Eversense E3 / XL (180-day) | Senseonics | FDA PMA Approved |
| Next-Generation CGM System | Senseonics | Research & Development |